(Q38815234)

6 September 2017

0 references

Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials (English)

1 reference

6 September 2017

0 references

1 reference

1 reference

Sumit Kunwar

1

1 reference

6 September 2017

Khagendra Dahal

series ordinal

2

1 reference

6 September 2017

Sharan Sharma

series ordinal

3

1 reference

6 September 2017

publication date

22 April 2016

1 reference

Rheumatology International

6 September 2017

published in

1 reference

6 September 2017

volume

36

1 reference

6 September 2017

issue

8

1 reference

6 September 2017

page(s)

1065-1075

1 reference

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Structural basis of receptor sharing by interleukin 17 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Interleukin-17 family and IL-17 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Are T cells in rheumatoid synovium aggressors or bystanders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Interleukin-23: as a drug target for autoimmune inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

IL-17 as a future therapeutic target for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3480-9

High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism

21 January 2018

1 reference

12 December 2020

Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo

1 reference

12 December 2020

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

1 reference

12 December 2020

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

1 reference

12 December 2020

Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium

1 reference

12 December 2020

Role of Th17 cells in human autoimmune arthritis

1 reference

12 December 2020

Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

10.1007/S00296-016-3480-9

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1030372532

0 references

1 reference